Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer.

Clinical Breast Cancer
Zaida MoranteHenry L Gómez

Abstract

Adjuvant chemotherapy decreases the recurrence risk and improves survival rates; however, it is unclear whether a delayed initiation is associated with adverse outcomes, especially in triple negative breast cancer (TNBC). In this study, we evaluated the influence of the time to start adjuvant chemotherapy (TTC) in the outcomes of TNBC. We retrospectively analyzed 15 years of data from patients with TNBC who received adjuvant chemotherapy at the Instituto Nacional de Enfermedades Neoplasicas (Lima, Peru). TTC was categorized into 4 groups: ≤ 30, 31 to 60, 61 to 90, and ≥ 91 days. We evaluated overall survival (OS) and distant recurrence-free survival (DRFS). Cox proportional hazard models were used to identify prognostic factors. In total, 687 patients were included. The mean age at diagnosis was 49.1 years (SD, 11.8 years), and most (62.6%) patients had pathologic stage T2. The median TTC was 48.1 days (SD, 27.4 days); 189 (27.5%) received chemotherapy ≤ 30 days; 329 (47.9%), between 31 and 60 days; 115 (16.7%), between 61 and 90 days; and 54 (7.9%) in ≥ 90 days. In the multivariate analysis, a TTC between 31 and 60 days (hazard ratio [HR], 1.78; 95% confidence interval [CI], 1.17-2.72), 61 and 90 days (HR, 2.38; 95%CI, 1.43-3....Continue Reading

References

Apr 4, 2006·Breast Cancer Research and Treatment·Dawn L HershmanAlfred I Neugut
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Sep 25, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S J DawsonC Caldas
Feb 19, 2010·The Cancer Journal·Steven J Isakoff
Nov 22, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard J BleicherBrian L Egleston
Nov 28, 2013·The Oncologist·Cynthia Villarreal-GarzaCarlos Barrios
Jan 29, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Debora de Melo GagliatoMariana Chavez-Macgregor
Mar 15, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BinesE D Saad
Sep 24, 2015·Journal of Surgical Oncology·Colleen M O'Kelly PriddyJulie E Lang
Dec 15, 2015·JAMA Oncology·Mariana Chavez-MacGregorSharon H Giordano
Feb 18, 2016·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·I T RubioV Marco
Apr 18, 2017·Molecular and Clinical Oncology·Alejandro YábarRaúl E Velarde-López
Jan 18, 2018·Cancer·Melissa Pilewskie, Monica Morrow
Feb 1, 2018·Annals of Surgical Oncology·Luis A RibaTed A James

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.